» Articles » PMID: 6498066

Oral Contraceptive Use and Malignant Melanoma in Australia

Overview
Journal Br J Cancer
Specialty Oncology
Date 1984 Nov 1
PMID 6498066
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

In a case control study of 287 women aged 15-24 years with malignant melanoma and 574 matched controls, findings relating to oral contraceptive use and other hormone use are reported. Ever having used oral contraceptives was not associated with an increased risk of melanoma (relative risk for ever use of the pill = 1.0). Women with melanoma were, however, more likely to have taken oral contraceptives for long periods of time in the past, the relative risk associated with oral contraceptive use for a total duration of 5 years or longer which had begun at least 10 years before the melanoma was diagnosed being 1.5 (95% confidence interval 1.03 to 2.14) This elevated risk persisted after controlling for the reported hair and skin colour, frequency of moles on the body, place of birth, and measures of sunlight and fluorescent light exposure. Cases were more likely than controls to have used hormones to regulate their periods, hormonal replacement therapy and be given hormone injections to suppress lactation, the respective relative risks being 1.9, 1.4 and 1.4, but none differed significantly from 1.0. These findings suggest that prolonged oral contraceptive use may, after a lag of 10 years or so, increase the risk of malignant melanoma.

Citing Articles

Unraveling the controversy: exploring the link between sex hormones and skin cancers through a meta-analysis and systematic review.

Zhao T, Li C, Zhong A, Yun J, Chen J Arch Dermatol Res. 2025; 317(1):292.

PMID: 39825969 DOI: 10.1007/s00403-024-03791-7.


Exogenous Hormone Factors in Relation to the Risk of Malignant Melanoma in Women: A Systematic Review and Meta-Analysis.

Chiavarini M, Naldini G, Giacchetta I, Fabiani R Cancers (Basel). 2022; 14(13).

PMID: 35804961 PMC: 9264834. DOI: 10.3390/cancers14133192.


Hormone therapy and melanoma in women.

Hill M, Cartron A, Burgoyne M, Driscoll M Int J Womens Dermatol. 2022; 7(5Part B):692-696.

PMID: 35028367 PMC: 8714603. DOI: 10.1016/j.ijwd.2021.06.005.


Effects of Exogenous Hormones and Reproductive Factors on Female Melanoma: A Meta-Analysis.

Sun Q, Sun H, Cong L, Zheng Y, Wu N, Cong X Clin Epidemiol. 2020; 12:1183-1203.

PMID: 33149695 PMC: 7605627. DOI: 10.2147/CLEP.S273566.


Estrogen Receptors and Melanoma: A Review.

Dika E, Patrizi A, Lambertini M, Manuelpillai N, Fiorentino M, Altimari A Cells. 2019; 8(11).

PMID: 31752344 PMC: 6912660. DOI: 10.3390/cells8111463.


References
1.
Beral V, RAMCHARAN S, Faris R . Malignant melanoma and oral contraceptive use among women in California. Br J Cancer. 1977; 36(6):804-9. PMC: 2025573. DOI: 10.1038/bjc.1977.265. View

2.
Adam S, Sheaves J, Wright N, Mosser G, Harris R, Vessey M . A case-control study of the possible association between oral contraceptives and malignant melanoma. Br J Cancer. 1981; 44(1):45-50. PMC: 2010646. DOI: 10.1038/bjc.1981.145. View

3.
Bain C, Hennekens C, Speizer F, Rosner B, Willett W, Belanger C . Oral contraceptive use and malignant melanoma. J Natl Cancer Inst. 1982; 68(4):537-9. View

4.
Beral V, Evans S, Shaw H, MILTON G . Malignant melanoma and exposure to fluorescent lighting at work. Lancet. 1982; 2(8293):290-3. DOI: 10.1016/s0140-6736(82)90270-7. View

5.
Holly E, Weiss N, Liff J . Cutaneous melanoma in relation to exogenous hormones and reproductive factors. J Natl Cancer Inst. 1983; 70(5):827-31. View